Finally, based on our findings and previous studies, we propose a meaningful hypothesis: inducing M1 macrophages in vitro, followed by ITGB2 knockout, and then reinfusing these ITGB2‐deficient M1 macrophages into patients may represent a feasible new immunotherapeutic approach, offering a novel strategy for ESCC immunotherapy. This evidence concerns the gene ITGB2 and esophageal squamous cell carcinoma.